Thamake, Sanjay
Merck & Co., Inc., Rahway, NJ, USA (United States)
2 papers on CoChat
Most cited papers
- Verified
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 305
- Verified
Phase II Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2020) · Journal of Clinical Oncology
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 42
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free